ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.
Proceeds from the financing will be used in the ongoing research and development of Nuance's existing products and business development of potential new assets.
Lead Product(s):
Polysaccharide iron complex
Therapeutic Area:HematologyProduct Name: Li Fei Neng
Highest Development Status:ApprovedProduct Type: Small molecule